|Bid||88.32 x 2200|
|Ask||88.36 x 1000|
|Day's Range||88.16 - 88.49|
|52 Week Range||72.30 - 94.19|
|Beta (3Y Monthly)||0.85|
|PE Ratio (TTM)||15.46|
|Forward Dividend & Yield||2.98 (3.34%)|
|1y Target Est||N/A|
Novartis and Audentes could hold the keys to curing a pair of genetic diseases — but they will cost $4 million to $5 million apiece, an analyst predicted Monday.
Ligand (LGND) beats earnings and sales estimates in the third quarter of 2018 and raises full-year guidance for the second straight quarter.
Novartis said on Thursday its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug. The drug is made by China's Zhejiang Huahai Pharmaceutical Co Ltd. Last month, the European Medicines Agency placed the firm under high supervision after a probable carcinogen was found in its blood pressure drug valsartan. A review was extended to other 'sartan' medicines, including candesartan, irbesartan, losartan, olmesartan and valsartan, after very low levels of a carcinogen was found in losartan made by Hetero Labs in India.
On June 4, the FDA issued a press release announcing regulatory approval for a biosimilar version of Amgen’s (AMGN) Neulasta and Mylan’s (MYL) Fulphilia. On September 20, the European Medicines Agency issued a press release announcing a positive opinion from the Committee for Medicinal Products for Human Use for Fulphila. According to Mylan’s investor presentation, Fulphila is targeting a global market opportunity worth more than $5.0 billion.
The company's development-stage SMA treatment was supposed to knock out the market leader, but now it may be the one at risk of an upset.
The fast-growing company is consolidating into a larger headquarters in Rockville — not far from its current home.
Amgen's newer drugs, Prolia, Xgeva, Kyprolis, are driving sales. Lower sales of mature drugs like Enbrel and biosimilar competition for Neulasta/Epogen are concerns.
Ligand's (LGND) partnered programs - Kyprolis and Promacta - using its Captisol formulation technology are expected to drive milestone and royalty payments in third-quarter 2018.
The company, which had hired close to 90 people leading up to its first drug approval, has been cutting jobs since the FDA said its antibiotic could be used in one type of infection but not another.
Novartis International AG said on Friday that its Sandoz division is abandoning an effort to gain U.S. regulatory approval for a biosimilar of rituximab, a medication used to treat certain cancer and rheumatoid arthritis. The decision comes after the U.S. Food and Drug Administration (FDA) sought additional information to support the company's application for the drug, which is approved already in the EU, Switzerland, Japan and Australia, the company said in a statement. "We are disappointed to have to make this decision and stand behind the safety, efficacy and quality of our medicine," said Stefan Hendriks, global head of biopharmaceuticals at Sandoz.
Merck & Co.’s (MRK) Januvia generated revenues of $927 million in the third quarter, reflecting an ~8% YoY (year-over-year) decline. In the US and international markets, Januvia generated revenues of $498 million and $429 million, respectively, reflecting a ~17% YoY decline and a ~45 YoY growth.
Children's Hospital of Philadelphia expects to double its viral vector manufacturing facility, to support cell and gene therapy, in its new space.
The developer behind some of the Bay Area's largest biotech and life sciences campuses is poised to begin construction on another on the Peninsula, which could become the next big biotech hub.
Aduro's loss (ADRO) betters estimates in Q3. However, lower license and collaboration fees induce a dip in year-over-year revenues.
The U.S. Food and Drug Administration (FDA) has approved Novartis AG's copy of Humira, the world's bestselling prescription medicine developed by U.S.-based AbbVie Inc, the agency's website showed on Wednesday. Although approved, Novartis' Sandoz unit can only begin U.S. sales of Humira's biosimilar in 2023, according to a licensing agreement sealed with AbbVie this month. The biosimilar, Hyrimoz, is approved https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761071lbl.pdf for treating several diseases, including rheumatoid arthritis, the FDA said.